Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × troxacitabine × Clear all
NCT00104468 2008-01-17

Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 1/2 Terminated
50 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00129948 2006-11-03

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 2 Terminated
211 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡